NMPA Approves Suzhou MicroPort Joint Medical Technology’s Zirconium Niobium Alloy Femoral Head for Hip Replacement
The National Medical Products Administration (NMPA) has granted marketing approval to Suzhou MicroPort Joint Medical...
Product approvals
Sinocelltech Group Receives NMPA Approval for Biosimilar Version of Humira
China-based Sinocelltech Group Ltd (SHA: 688520) has announced that it has received market approval from...
China Medical System’s Diazepam Nasal Spray Receives NMPA Approval for Cluster Seizures
China-based China Medical System Holdings Ltd (CMS; HKG: 0867) has announced receiving New Drug Application...
AstraZeneca’s Soliris Secures Third Indication for Myasthenia Gravis in China
UK pharmaceutical giant AstraZeneca (AZ, NASDAQ: AZN) has announced that its Soliris (eculizumab), a first-in-class...
Salubris Pharmaceuticals’ Enarodustat Gains NMPA Approval for Renal Anemia Treatment
China’s Shenzhen Salubris Pharmaceuticals Co., Ltd (SHE: 002294) has announced receiving market approval from the...
NMPA Approves Shanghai Magic Medicine’s Innovative Multimodal Tumor Treatment System
The National Medical Products Administration (NMPA) has granted marketing approval to Shanghai Magic Medicine’s multimodal...
NMPA Approves Betta Pharmaceuticals’ Vorolanib for Second-Line RCC Treatment in Combination with Everolimus
The National Medical Products Administration (NMPA) has granted approval for Betta Pharmaceuticals Co., Ltd’s (SHE:...
NMPA Approves Shenzhen Core Medical’s Implantable Left Ventricular Assist System
The National Medical Products Administration (NMPA) has issued market approval for the implantable left ventricular...
NMPA Clears Medtronic’s Corindus for Marketing of Advanced Coronary Surgery Systems
The National Medical Products Administration (NMPA) has granted marketing approval for the “coronary artery interventional...
NMPA Grants Market Approval for Lanzhou Kejin Taiji’s Carbon Ion Therapy System
The National Medical Products Administration (NMPA) in China has issued market approval to Lanzhou Kejin...
CStone Pharmaceuticals and Blueprint Medicines’ Ayvakit Wins FDA Approval for ISM Treatment
Partners CStone Pharmaceuticals (HKG: 2616) and Blueprint Medicines have announced that the US FDA has...
CANbridge Pharmaceuticals’ Maralixibat Approved by NMPA for Alagille Syndrome
China-based rare disease specialist CANbridge Pharmaceuticals Inc., (HKG: 1228) has announced receiving market approval from...
Betta Pharmaceuticals’ Befotertinib Approved by China’s NMPA for EGFR-Mutated NSCLC
China-based Betta Pharmaceuticals Co., Ltd (SHE: 300558) has announced receiving market approval from the National...
CMS Receives NMPA Approval for Tildrakizumab for Plaque Psoriasis Treatment
China Medical System Holdings (CMS; HKG: 0867) has announced receiving marketing approval from the National...
BeiGene’s Brukinsa Receives Canadian Approval for Chronic Lymphocytic Leukemia
China-based BeiGene Ltd (NASDAQ: BGNE, HKG: 6160, SHA: 688235) has announced that its Bruton’s tyrosine...
Chia Tai Tianqing’s Biosimilar Rituximab Approved by China’s NMPA for Lymphoma Treatments
China-based Chia Tai Tianqing has announced receiving a market approval from the National Medical Products...
MabPharm’s CMAB007 Receives NMPA Approval for IgE-Mediated Asthma Treatment
Taizhou-based monoclonal antibody (mAb) biosimliars specialist MabPharm Ltd (HKG: 2181) has announced that it has...
BeiGene’s Tislelizumab Approved in China for First-Line Esophageal Squamous Cell Carcinoma
BeiGene (NASDAQ: BGNE) has announced that its programmed death-1 (PD-1) inhibitor, tislelizumab, has been approved...
Bayer’s Copanlisib (Aliqopa) Approved by NMPA for Recurrent Follicular Lymphoma
The National Medical Products Administration (NMPA) has indicated on its website that Bayer’s (ETR: BAYN)...
MicroPort MedBot Receives NMPA Approval for Mona Lisa Prostate Puncture Robot System
Shanghai MicroPort MedBot (Group) Co., Ltd (HKG: 2252) has announced that it has received marketing...